Phase II trial of transcatheter arterial chemoembolization [cisplatin] (TACE) plus oral sorafenib (BAY 43-9006, Nexavar) for unresectable hepatocellular carcinoma (HCC)

Trial Profile

Phase II trial of transcatheter arterial chemoembolization [cisplatin] (TACE) plus oral sorafenib (BAY 43-9006, Nexavar) for unresectable hepatocellular carcinoma (HCC)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Dec 2016

At a glance

  • Drugs Sorafenib (Primary) ; Cisplatin
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Apr 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 16 Dec 2009 Planned end date changed from 1 Jan 2009 to 1 Jun 2010 as reported by ClinicalTrials.gov.
    • 02 Jun 2008 Status changed from initiated to recruiting as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top